[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100372519":3},{"organization":4,"armGroups":7,"interventions":25,"overallOfficials":45,"centralContacts":50,"locations":57,"responsibleParty":89,"collaborators":93,"id":96,"slug":97,"hasResults":98,"nctId":99,"briefTitle":100,"officialTitle":101,"acronym":102,"eligibilityCriteria":103,"healthyVolunteers":104,"sex":105,"minAge":106,"maxAge":107,"enrollmentInfo":108,"targetDuration":55,"studyType":111,"phases":112,"briefSummary":114,"conditions":115,"keywords":120,"overallStatus":60,"whyStopped":55,"lastUpdateSubmitDate":124,"lastUpdatePostDateStruct":125,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":133},{"fullName":5,"class":6},"George Washington University","OTHER",[8,14,19],{"label":9,"type":10,"description":11,"interventionNames":12},"Ropivacaine","EXPERIMENTAL","Subjects will receive a continuous intraperitoneal infusion of ropivacaine",[13],"Drug: Ropivacaine Infusion from ON-Q Pump",{"label":15,"type":10,"description":16,"interventionNames":17},"Ropivacaine + Ketorolac","Subjects will receive a continuous intraperitoneal infusion of ropivacaine + ketorolac",[18],"Drug: Ropivacaine + Ketorolac Infusion from ON-Q Pump",{"label":20,"type":21,"description":22,"interventionNames":23},"Normal Saline","PLACEBO_COMPARATOR","Subjects will receive a continuous intraperitoneal infusion of normal saline",[24],"Drug: Normal Saline Infusion from ON-Q Pump",[26,33,39],{"type":27,"name":28,"description":29,"armGroupLabels":30,"otherNames":31},"DRUG","Ropivacaine Infusion from ON-Q Pump","Infusion of 0.2% ropivacaine at 8 mL\u002Fhour for 72 hours",[9],[32],"Naropin",{"type":27,"name":34,"description":35,"armGroupLabels":36,"otherNames":37},"Ropivacaine + Ketorolac Infusion from ON-Q Pump","Infusion of 0.2% ropivacaine + 30 mg ketorolac at 8 mL\u002Fhour for 72 hours",[15],[32,38],"Toradol",{"type":27,"name":40,"description":41,"armGroupLabels":42,"otherNames":43},"Normal Saline Infusion from ON-Q Pump","Infusion of 0.9% normal saline at 8 mL\u002Fhour for 72 hours",[20],[44],"Saline solution",[46],{"name":47,"affiliation":48,"role":49},"Jennifer Keller, MD","Physician","PRINCIPAL_INVESTIGATOR",[51],{"name":52,"role":53,"phone":54,"phoneExt":55,"email":56},"Radwa Aly","CONTACT","202 677 6209",null,"raly@mfa.gwu.edu",[58,78],{"facility":59,"status":60,"city":61,"state":62,"zip":63,"country":64,"countryCode":65,"cosmosGeoPoint":66,"geoPoint":71,"contacts":72},"MedStar Washington Hospital Center","RECRUITING","Washington D.C.","District of Columbia","20010","United States","US",{"type":67,"coordinates":68},"Point",[69,70],-77.03637,38.89511,{"lat":70,"lon":69},[73,77],{"name":74,"role":53,"phone":75,"phoneExt":55,"email":76},"James Robinson, MD","202-877-0526","james.k.robinson@medstar.net",{"name":74,"role":49,"phone":55,"phoneExt":55,"email":55},{"facility":79,"status":60,"city":61,"state":62,"zip":80,"country":64,"countryCode":65,"cosmosGeoPoint":81,"geoPoint":83,"contacts":84},"The GW Medical Faculty Associates","20037",{"type":67,"coordinates":82},[69,70],{"lat":70,"lon":69},[85,88],{"name":47,"role":53,"phone":86,"phoneExt":55,"email":87},"202 741 2524","jkeller@mfa.gwu.edu",{"name":47,"role":49,"phone":55,"phoneExt":55,"email":55},{"type":90,"investigatorFullName":91,"investigatorTitle":92,"investigatorAffiliation":5,"oldNameTitle":55,"oldOrganization":55},"SPONSOR_INVESTIGATOR","Ying Liu","PI",[94],{"name":95,"class":6},"Avanos Medical","100372519","phase-4-intraperitoneal-infusion-of-analgesic-for-postoperative-pain-management-100372519",false,"NCT04130464","Intraperitoneal Infusion of Analgesic for Postoperative Pain Management","The Impact of the Continuous Infusion of Intraperitoneal Analgesics on Postoperative Pain After Minimally Invasive Hysterectomy: a Randomized Controlled Trial","ON-Q","Inclusion Criteria:\n\n* Hysterectomy planned for a benign gynecologic reason (no evidence of, or concern for, malignancy in the cervix, uterus, tubes or ovaries. Benign gynecologic reasons to have a hysterectomy include fibroids, abnormal uterine bleeding, endometriosis, and pelvic pain.)\n* Patient is scheduled to have surgery with a fellowship trained minimally invasive gynecologic surgeons at one of the study sites.\n* Patient is planned for a robotic assisted total laparoscopic hysterectomy (RA-TLH) or a total laparoscopic hysterectomy (TLH).\n* Patient is capable of informed consent.\n* Patient is capable of completing the questionnaires.\n\nExclusion Criteria:\n\n* Concern for malignancy\n* The procedure is scheduled outside MIGS department.\n* Allergy to any study related medication (i.e. Ketorolac and Ropivacaine)\n* Patient is enrolled in another pain management study.",true,"FEMALE","18 Years","65 Years",{"count":109,"type":110},120,"ESTIMATED","INTERVENTIONAL",[113],"PHASE4","The study is a prospective, double-blinded, placebo-controlled multi-center trial to measure if postoperative pain and the amount of narcotics used are reduced by a clinically significant amount in women undergoing minimally invasive hysterectomy receiving a continuous infusion of intraperitoneal (IP) local anesthetic (LA) or a continuous infusion of LA combined with an NSAID compared with a control group who receives only 0.9% normal saline.",[116,117,118,119],"Hysterectomy","Gynecologic Surgical Procedures","Narcotic Use","Pain, Postoperative",[121,122,9,123],"Intraperitoneal","Pain Pump","Ketorolac Tromethamine","2026-04-03",{"date":126,"type":127},"2026-04-09","ACTUAL",{"date":129,"type":127},"2019-09-30",{"date":131,"type":110},"2026-12",{"name":91,"class":6},2]